Serum Concentrations of Fibroblast Growth Factor 19 in Patients With Obesity and Type 2 Diabetes Mellitus: the Influence of Acute Hyperinsulinemia, Very-Low Calorie Diet and PPAR-α Agonist Treatment

Abstract

The aim of our study was to measure serum concentrations of fibroblast growth factor 19 (FGF-19) in patients with obesity (OB), obesity and type 2 diabetes mellitus (T2DM) and healthy subjects (C) at baseline and after selected interventions. We measured serum FGF-19 levels and other biochemical and hormonal parameters in 29 OB and 19 T2DM females and 30 sex- and age-matched control subjects. The interventions were acute hyperinsulinemia during isoglycemic-hyperinsulinemic clamp (n=11 for T2DM and 10 for C), very-low calorie diet (VLCD, n=12 for OB) and 3 months treatment with PPAR-α agonist fenofibrate (n=11 for T2DM). Baseline serum FGF-19 levels were significantly lower in OB relative to C group (132.1±12.7 vs. 202.2±16.7 pg/ml, p<0.05), while no significant difference was observed between T2DM and OB or control group. Acute hyperinsulinemia tended to decrease FGF-19 levels in both healthy and T2DM subjects. Three weeks of VLCD in OB group had no significant effect on FGF-19, whereas three months of fenofibrate treatment markedly reduced FGF-19 levels in T2DM patients (194.58±26.2 vs. 107.47±25.0 pg/ml, p<0.05). We conclude that FGF-19 levels in our study were at least partially dependent upon nutritional status, but were not related to parameters of glucose metabolism or insulin sensitivity.

Laparoscopic sleeve gastrectomy differentially affects serum concentrations of FGF‐19 and FGF‐21 in morbidly obese subjects

“…The observation of decreased levels of FGF-19 in obese patients is in agreement with our previous results in obese patients with type 2 diabetes (31). In contrast, other studies in patients with fatty liver disease (16) and type 2 diabetes (17) did not observe any differences in circulating FGF-19 between the patients and healthy control groups.…”

An Overview of FGF19 and FGF21: The Therapeutic Role in the Treatment of the Metabolic Disorders and Obesity

“…Elevated levels of FGF19 have been observed in patients with chronic hemodialysis and extrahepatic cholestasis [75,76]. In contrast, reduced concentrations were found in patients with type 2 diabetes, non-alcoholic fatty liver disease (NAFLD), primary bile acid malabsorption, and inflammatory bowel disease (IBD) [77][78][79].…”

Intestinal-derived FGF15 preserves muscle and bone mass following sleeve gastrectomy

“…Circulating FGF19 levels are reduced in individuals with metabolic disorders and nonalcoholic fatty liver disease (NAFLD). FGF19 levels are lower in obese patients, without strong association to glucose metabolism or insulin sensitivity (Gallego-Escuredo et al, 2015;Gomez-Ambrosi et al, 2017;Haluzikova et al, 2013;Mraz et al, 2011;Renner et al, 2014).…”

“…Circulating FGF19 levels are lower in obese patients (Gallego-Escuredo et al, 2015;Gomez-Ambrosi et al, 2017;Haluzikova et al, 2013;Mraz et al, 2011;Renner et al, 2014) and patients with impaired glucose metabolism or insulin sensitivity (Barutcuoglu et al, 2011;Sonne et al, 2016) and nonalcoholic fatty liver disease (NAFLD) (Eren et al, 2012;Jiao et al, 2018). This highlights the relationship of FGF19 with body weight and metabolism.…”